FGFR Fibroblast Growth Factor Receptor

Inhibitors

Cat.No.	Name	Information
M1721	AZD4547	AZD4547 is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively.
M1840	BGJ398 (Infigratinib)	BGJ398 (Infigratinib) is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
M21498	Bemarituzumab	Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).
M20223	WAY-625530	WAY-625530 is a Fibroblast Growth Factor Receptor 1 Kinase inhibitor.
M20221	WAY-621856	WAY-621856 is a FGFR inhibitor.
M20193	WAY-603814	WAY-603814 is a FGFR1 inhibitor
M20183	WAY-600868	WAY-600868 is a FGFR3 inhibitor.
M20165	WAY-353890	WAY-353890 is a inhibitor of protein kinase FGFR1
M20050	WAY-272449	WAY-272449 is a FGFR1 inhibitor.
M20048	WAY-272130	WAY-272130 is a FGFR1 inhibitor.
M20039	WAY-270599	WAY-270599 is a FGFR1 inhibitor
M14896	Rogaratinib	Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor.
M14895	Infigratinib phosphate	Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
M14894	Ferulic acid sodium	Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
M13357	EOC317	EOC317 (ACTB-1003) is an orally available kinase inhibitor that inhibits FGFR1, VEGFR2, and tie-2 with IC50 values of 6,2, and 4 nM, respectively.
M10737	PRN1371	PRN1371 is a highly selective and potent inhibitor of FGFR1-4 and CSF1R against FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R IC50 The values are 0.6, 1.3, 4.1, 19.3, and 8.1 nM, respectively.
M10590	Alofanib (RPT835)	Alofanib (RPT835) is a novel selective allosteric inhibitor of FGFR2 and has a dramatic inhibitory effect with IC50 <10 nM on FGF2-induced phoshphorylation of FRS2a in KATO III cells.
M10518	ASP5878	ASP5878 is a novel selective FGFR inhibitor with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3 and 4, respectively.
M10048	PF-05231023	PF-05231023 is an FGF21-receptor agonist, it is also a potential treatment for T2DM.
M10026	Futibatinib (TAS-120)	Futibatinib (TAS-120) is an oral bioavailable, highly selective and irreversible FGFR inhibitor with IC50 of 3.9, 1.3, 1.6 and 8.3 nM against the four FGFR 1-4 subtypes, respectively. Futibatinib inhibited mutant and wild-type FGFR2 with IC50 similarity (wild-type FGFR2=0.9 nM; V5651 = 1 to 3 nM; N550H = 3.6 nM. E566G = 2.4 nM).
M9715	Erdafitinib	Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan FGFR inhibitor with potential antineoplastic activity.
M9596	Pemigatinib	Pemigatinib (INCB054828) is an orally effective, selective FGFR inhibitor with IC50 values of 0.4 nM, 0.5 nM, 1.2 nM, and 30 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.Pemigatinib exhibited anti-tumor activity in mouse xenograft models with FGFR1, FGFR2, or FGFR3-altered human tumors in a mouse xenograft model exhibiting antitumor activity.

Signaling Pathways

Product Type

FGFR Fibroblast Growth Factor Receptor

Get to Know Us

Customer Support

Resources

Contact Us